| Carcinoma breast stage IV
Abraxane vs Phesgo
Side-by-side clinical, coverage, and cost comparison for carcinoma breast stage iv.Deep comparison between: Abraxane vs Phesgo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPhesgo has a higher rate of injection site reactions vs Abraxane based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Phesgo but not Abraxane, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Abraxane
Phesgo
At A Glance
IV infusion
Weekly to every 3 weeks
Microtubule inhibitor
SC injection
Every 3 weeks
HER2/neu receptor antagonist
Indications
- Carcinoma breast stage IV
- Non-Small Cell Lung Carcinoma
- Adenocarcinoma of pancreas
- HER2-positive carcinoma of breast
- Inflammatory Breast Carcinoma
- Locally advanced breast cancer
- Carcinoma breast stage IV
Dosing
Carcinoma breast stage IV 260 mg/m2 IV over 30 minutes every 3 weeks.
Non-Small Cell Lung Carcinoma 100 mg/m2 IV over 30 minutes on Days 1, 8, and 15 of each 21-day cycle; administer carboplatin on Day 1 of each 21-day cycle immediately after ABRAXANE.
Adenocarcinoma of pancreas 125 mg/m2 IV over 30-40 minutes on Days 1, 8, and 15 of each 28-day cycle; administer gemcitabine on Days 1, 8, and 15 of each 28-day cycle immediately after ABRAXANE.
HER2-positive carcinoma of breast, Inflammatory Breast Carcinoma, Locally advanced breast cancer Initial dose 1,200 mg pertuzumab / 600 mg trastuzumab / 30,000 units hyaluronidase SC over ~8 min, then maintenance 600 mg pertuzumab / 600 mg trastuzumab / 20,000 units hyaluronidase SC over ~5 min every 3 weeks with chemotherapy; neoadjuvant: 3-6 preoperative cycles then continue to complete 18 total cycles; adjuvant: up to 18 cycles (1 year) starting Day 1 of first taxane-containing cycle.
Carcinoma breast stage IV Initial dose 1,200 mg pertuzumab / 600 mg trastuzumab / 30,000 units hyaluronidase SC over ~8 min, then maintenance 600 mg pertuzumab / 600 mg trastuzumab / 20,000 units hyaluronidase SC over ~5 min every 3 weeks with docetaxel until disease progression or unmanageable toxicity.
Contraindications
- Baseline neutrophil count below 1500 cells/mm3
- History of severe hypersensitivity reaction to ABRAXANE
- Known hypersensitivity to pertuzumab, trastuzumab, hyaluronidase, or any excipient of PHESGO
Adverse Reactions
Most common (>=20%) Alopecia, neutropenia, sensory/peripheral neuropathy, abnormal ECG, fatigue/asthenia, myalgia/arthralgia, AST elevation, alkaline phosphatase elevation, anemia, nausea, infections, diarrhea, thrombocytopenia, peripheral edema, pyrexia, vomiting, decreased appetite, rash, dehydration
Serious Anemia, pneumonia, pyrexia, dehydration, vomiting
Postmarketing Severe hypersensitivity reactions, congestive heart failure, left ventricular dysfunction, atrioventricular block, pneumonitis, interstitial pneumonia, pulmonary embolism, cranial nerve palsies, vocal cord paresis, autonomic neuropathy, cystoid macular edema, hepatic necrosis, intestinal obstruction, intestinal perforation, pancreatitis, ischemic colitis, tumor lysis syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis
Most common (>=5%) Alopecia, nausea, diarrhea, anemia, asthenia, fatigue, stomatitis, myalgia, arthralgia, neutropenia, vomiting, constipation, headache, dysgeusia, decreased appetite, peripheral sensory neuropathy, mucosal inflammation, injection site reaction, radiation skin injury, insomnia, cough
Serious Febrile neutropenia, neutropenic sepsis, neutrophil count decreased, cardiomyopathy, pulmonary toxicity
Postmarketing Glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Pharmacology
ABRAXANE is a microtubule inhibitor that promotes assembly and stabilization of microtubules from tubulin dimers, inhibiting the normal dynamic reorganization of the microtubule network essential for vital interphase and mitotic cellular functions.
Pertuzumab blocks HER2 heterodimerization at subdomain II to inhibit MAP kinase and PI3K signaling, trastuzumab binds subdomain IV to inhibit HER2-mediated cell proliferation, and together they augment antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor cells; hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability and enable systemic absorption.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Abraxane
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
Phesgo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Abraxane
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Phesgo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Abraxane
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Phesgo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Abraxane.
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AbraxaneView full Abraxane profile
PhesgoView full Phesgo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.